Cover Image
市場調查報告書

全球人體生長荷爾蒙市場

Global Human Growth Hormone Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 320559
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
全球人體生長荷爾蒙市場 Global Human Growth Hormone Market 2015-2019
出版日期: 2014年11月26日 內容資訊: 英文 87 Pages
簡介

全球人體生長荷爾蒙市場預計從2014年到2019年的期間,以4.22%的年複合成長率擴大。

本報告提供全球人體生長荷爾蒙市場的詳細調查分析、市場規模與成長率、主要的市場趨勢、市場成長的促進要素、市場成長的課題,及主要企業簡介等彙整,為您概述為以下內容。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 人體生長荷爾蒙

  • 簡介
  • 人體生長荷爾蒙
  • 作用機制
  • 生長激素層級
  • 人口族群
  • 生長激素層級(ng/mL)
  • 生長激素層級的差異

第7章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 區域區隔

  • 南北美洲的人體生長荷爾蒙市場
  • EMEA(歐洲、中東、非洲)的人體生長荷爾蒙市場
  • APAC(亞太地區)的人體生長荷爾蒙市場

第9章 主要國家

  • 美國
  • 日本
  • 德國
  • 義大利

第10章 購買標準

第11章 市場成長的促進要素

第12章 成長因素與其影響

第13章 市場課題

第14章 成長因素與課題的影響

第15章 市場趨勢

第16章 趨勢與其影響

第17章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他有潛力的供應商

第18章 主要供應商分析

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novo Nordisk
  • Pfizer

第19章 相關報告

圖表一覽

目錄
Product Code: IRTNTR4664

About Human Growth Hormones

Growth hormone is a proteinaceous hormone consisting of 191 amino acid residues and is secreted by the anterior part of the pituitary gland. In children and adolescents, growth hormones are produced and secreted in high levels and promote linear growth. However, as an individual reaches the adult stage, its level starts declining and primarily perform anabolic functions. The direct activity of a human growth hormone, exerted via its interaction with the human growth hormone receptor, includes metabolic and anti-insulin activities.

TechNavio's analysts forecast the Global Human Growth Hormone market to grow at a CAGR of 4.22 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Human Growth Hormone market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of innovator human growth hormone drugs and their technologies.

TechNavio's report, Global Human Growth Hormone Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Human Growth Hormone market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Merck Serono
  • Novo Nordisk
  • Pfizer

Other Prominent Vendors

  • Anhui Anke Biotechnology (Group)
  • BioPartners
  • Eli Lilly
  • Ferring Pharmaceuticals
  • GeneScience Pharmaceuticals
  • Ipsen
  • LG Life Sciences
  • Sandoz International
  • Teva Pharmaceutical Industries

Market Driver

  • Increased Demand for Human Growth Hormones
  • For a full, detailed list, view our report

Market Challenge

  • Intense Market Competition
  • For a full, detailed list, view our report

Market Trend

  • Advances in Technology
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Human Growth Hormone

    • 06.1.1. Introduction
    • 06.1.2. Human Growth Hormone
    • 06.1.3. Mechanism of Action
    • 06.1.4. Growth Hormone Levels
    • 06.1.5. Population Group
    • 06.1.6. Growth Hormone Levels (ng/mL)
    • 06.1.7. Growth Hormone Deficiency

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Geographical Segmentation

  • 08.1. Human Growth Hormone Market in Americas
    • 08.1.1. Market Size and Forecast
  • 08.2. Human Growth Hormone Market in EMEA Region
    • 08.2.1. Market Size and Forecast
  • 08.3. Human Growth Hormone Market in APAC Region
    • 08.3.1. Market Size and Forecast

09. Key Leading Countries

  • 09.1. US
  • 09.2. Japan
  • 09.3. Germany
  • 09.4. Italy

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2014
    • 17.2.1. Merck Serono
    • 17.2.2. Pfizer
    • 17.2.3. Novo Nordisk
    • 17.2.4. F. Hoffmann-La Roche
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. F. Hoffmann-La Roche
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Segmentation by Revenue 2012 and 2013
    • 18.1.5. Geographical Segmentation by Revenue
    • 18.1.6. Business Strategy
    • 18.1.7. Key Information
    • 18.1.8. SWOT Analysis
  • 18.2. Merck Serono
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Geographical Segmentation by Revenue 2013
    • 18.2.4. Business Strategy
    • 18.2.5. Recent Developments
    • 18.2.6. SWOT Analysis
  • 18.3. Novo Nordisk
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012 and 2013
    • 18.3.5. Sales by Geography
    • 18.3.6. Business Strategy
    • 18.3.7. Key Information
    • 18.3.8. SWOT Analysis
  • 18.4. Pfizer
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation by Revenue 2013
    • 18.4.4. Business Segmentation by Revenue 2012 and 2013
    • 18.4.5. Geographical Segmentation by Revenue
    • 18.4.6. Business Strategy
    • 18.4.7. Key Developments
    • 18.4.8. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: 3D Structure of Human Growth Hormone
  • Exhibit 3: UniProt Details for Human Growth Hormone
  • Exhibit 4: Regulation of Human Growth Hormone Secretion
  • Exhibit 5: Normal Growth Hormone Levels
  • Exhibit 6: Classification of Growth Hormone Deficiency by Age of Onset
  • Exhibit 7: Global Human Growth Hormone market 2014-2019 (US$ million)
  • Exhibit 8: NordiPenMate
  • Exhibit 9: Global Human Growth Hormone Market Segmentation by Geography 2014
  • Exhibit 10: Global Human Growth Hormone Market Segmentation by Geography 2019
  • Exhibit 11: Global Human Growth Hormone Market by Geography 2014-2019 (US$ million)
  • Exhibit 12: Global Human Growth Hormone Market by Geography 2014-2019
  • Exhibit 13: Global Human Growth Hormone Market Segmentation by Geography 2014-2019
  • Exhibit 14: YoY Growth Rate of Global Human Growth Hormone Market by Geography 2014-2019
  • Exhibit 15: Percentage Share of Global Human Growth Hormone Market by Geography 2014 and 2019
  • Exhibit 16: Human Growth Hormone Market in the Americas 2014-2019 (US$ million)
  • Exhibit 17: Human Growth Hormone Market in the EMEA Region 2014-2019 (US$ million)
  • Exhibit 18: Human Growth Hormone Market in the APAC Region 2014-2019 (US$ million)
  • Exhibit 19: NovoFine Needle
  • Exhibit 20: Market Share Comparison of Major Drugs 2014 H1
  • Exhibit 21: Parts of Click.easy
  • Exhibit 22: Easypod Drug Delivery Device
  • Exhibit 23: Parts of Cool.click 2
  • Exhibit 24: One.click Drug Delivery Device
  • Exhibit 25: Serojet Drug Delivery Device
  • Exhibit 26: Genotropin Miniquick
  • Exhibit 27: Parts of Genotropin Miniquick
  • Exhibit 28: Genotropin Mixer
  • Exhibit 29: Parts of Genotropin Mixer
  • Exhibit 30: Genotropin Pen
  • Exhibit 31: Parts of Genotropin Pen
  • Exhibit 32: Dosage Strengths of FlexPro
  • Exhibit 33: Dosage Strengths of NordiFlex
  • Exhibit 34: Dosage Strengths of Norditropin NordiLet
  • Exhibit 35: Dosage Strengths of Nordipen
  • Exhibit 36: Parts of Nordipen
  • Exhibit 37: Parts of Nutropin AQ NuSpin
  • Exhibit 38: Nutropin AQ NuSpin 20
  • Exhibit 39: Nutropin AQ NuSpin 10
  • Exhibit 40: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 41: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 42: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
  • Exhibit 43: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
  • Exhibit 44: Merck Serono: Geographical Segmentation by Revenue 2013
  • Exhibit 45: Novo Nordisk A/S: Business Segmentation by Revenue 2013
  • Exhibit 46: Novo Nordisk A/S: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 47: Novo Nordisk A/S: Sales by Geography 2013
  • Exhibit 48: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 49: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 50: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top